Epcoritamab Phase II Study with R-CHOP in Aggressive Non-Hodgkin Lymphoma Initiated
A Phase II, open-label, two-arm, multicenter study has been initiated to evaluate the efficacy and safety of epcoritamab in combination with R-CHOP chemotherapy for patients with newly diagnosed aggressive B-cell non-Hodgkin lymphoma.